| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jorge Manzanares, Leyre Urigüen, Gabriel Rubio, Tomás Palom. Role of endocannabinoid system in mental diseases. Neurotoxicity research. vol 6. issue 3. 2005-01-31. PMID:15325960. |
following the historical reports of the use of cannabis for medicinal purposes, recent research has highlighted the potential of cannabinoids to treat a wide variety of clinical disorders. |
2005-01-31 |
2023-08-12 |
Not clear |
| Jorge Manzanares, Leyre Urigüen, Gabriel Rubio, Tomás Palom. Role of endocannabinoid system in mental diseases. Neurotoxicity research. vol 6. issue 3. 2005-01-31. PMID:15325960. |
considering that cannabis or cannabinoid pharmaceutical preparations may no longer be exclusively recreational drugs but may also present potential therapeutic uses, it has become of great interest to analyze the neurobiological and behavioral consequences of their administration. |
2005-01-31 |
2023-08-12 |
Not clear |
| Young Hae Choi, Arno Hazekamp, Anja M G Peltenburg-Looman, Michel Frédérich, Cornelis Erkelens, Alfons W M Lefeber, Robert Verpoort. NMR assignments of the major cannabinoids and cannabiflavonoids isolated from flowers of Cannabis sativa. Phytochemical analysis : PCA. vol 15. issue 6. 2005-01-31. PMID:15595449. |
nmr assignments of the major cannabinoids and cannabiflavonoids isolated from flowers of cannabis sativa. |
2005-01-31 |
2023-08-12 |
Not clear |
| Angelo A Izz. Cannabinoids and intestinal motility: welcome to CB2 receptors. British journal of pharmacology. vol 142. issue 8. 2005-01-26. PMID:15277313. |
delta(9)-tetrahydrocannabinol (the active ingredient of marijuana), as well as endogenous and synthetic cannabinoids, exert many biological functions by activating two types of cannabinoid receptors, cb(1) receptors (expressed by central and peripheral neurons) and cb(2) receptors (that occur mainly in immune cells). |
2005-01-26 |
2023-08-12 |
rat |
| Javier Fernández-Ruiz, María Gómez, Mariluz Hernández, Rosario de Miguel, José A Ramo. Cannabinoids and gene expression during brain development. Neurotoxicity research. vol 6. issue 5. 2005-01-26. PMID:15545023. |
it is consumed even by women during pregnancy and lactation, which result in a variety of disturbances in the development of their offspring, because, like other habit-forming drugs, cannabinoids, the psychoactive ingredients of marijuana, can cross the placental barrier and be secreted in the maternal milk. |
2005-01-26 |
2023-08-12 |
Not clear |
| Arno Hazekamp, Young Hae Choi, Robert Verpoort. Quantitative analysis of cannabinoids from Cannabis sativa using 1H-NMR. Chemical & pharmaceutical bulletin. vol 52. issue 6. 2005-01-07. PMID:15187394. |
quantitative analysis of cannabinoids from cannabis sativa using 1h-nmr. |
2005-01-07 |
2023-08-12 |
Not clear |
| Arno Hazekamp, Young Hae Choi, Robert Verpoort. Quantitative analysis of cannabinoids from Cannabis sativa using 1H-NMR. Chemical & pharmaceutical bulletin. vol 52. issue 6. 2005-01-07. PMID:15187394. |
a (1)h-nmr method has been developed for the quantitative analysis of pure cannabinoids and for cannabinoids present in cannabis sativa plant material without any chromatographic purification. |
2005-01-07 |
2023-08-12 |
Not clear |
| Gregory T Carter, Vivian Ugald. Medical marijuana: emerging applications for the management of neurologic disorders. Physical medicine and rehabilitation clinics of North America. vol 15. issue 4. 2004-12-23. PMID:15458761. |
marijuana contains over 60 different types of cannabinoids, which are its medicinally active ingredients. |
2004-12-23 |
2023-08-12 |
Not clear |
| Daniele Piomell. The endogenous cannabinoid system and the treatment of marijuana dependence. Neuropharmacology. vol 47 Suppl 1. 2004-12-20. PMID:15464150. |
marijuana use may lead to adaptive changes in endocannabinoid signaling, and these changes might contribute to effects of marijuana as well as to the establishment of marijuana dependence. |
2004-12-20 |
2023-08-12 |
Not clear |
| Daniele Piomell. The endogenous cannabinoid system and the treatment of marijuana dependence. Neuropharmacology. vol 47 Suppl 1. 2004-12-20. PMID:15464150. |
in addition, i review recent progress on the development of pharmacological agents that interfere with endocannabinoid deactivation and discuss their potential utility in the treatment of marijuana dependence and other aspects of drug abuse. |
2004-12-20 |
2023-08-12 |
Not clear |
| J H Allen, G M de Moore, R Heddle, J C Twart. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut. vol 53. issue 11. 2004-12-02. PMID:15479672. |
cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. |
2004-12-02 |
2023-08-12 |
Not clear |
| Adèle Thomas, Ruth A Ross, Bijali Saha, Anu Mahadevan, Raj K Razdan, Roger G Pertwe. 6"-Azidohex-2"-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist. European journal of pharmacology. vol 487. issue 1-3. 2004-11-24. PMID:15033394. |
previous experiments with the mouse vas deferens have shown that cannabidiol produces surmountable antagonism of cannabinoid cb(1) receptor agonists at concentrations well below those at which it binds to cannabinoid cb(1) receptors and antagonizes alpha(1)-adrenoceptor agonists insurmountably. |
2004-11-24 |
2023-08-12 |
mouse |
| Adèle Thomas, Ruth A Ross, Bijali Saha, Anu Mahadevan, Raj K Razdan, Roger G Pertwe. 6"-Azidohex-2"-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist. European journal of pharmacology. vol 487. issue 1-3. 2004-11-24. PMID:15033394. |
we have now found that subtle changes in the structure of cannabidiol markedly influence its ability to produce each of these effects, suggesting the presence of specific pharmacological targets for this non-psychoactive cannabinoid. |
2004-11-24 |
2023-08-12 |
mouse |
| Adèle Thomas, Ruth A Ross, Bijali Saha, Anu Mahadevan, Raj K Razdan, Roger G Pertwe. 6"-Azidohex-2"-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist. European journal of pharmacology. vol 487. issue 1-3. 2004-11-24. PMID:15033394. |
however, it produced this antagonism with a potency that matched its cannabinoid cb(1) receptor affinity, suggesting that, unlike cannabidiol, it is a competitive cannabinoid cb(1) receptor antagonist. |
2004-11-24 |
2023-08-12 |
mouse |
| Catherine A Newton, Tangying Lu, Stanley J Nazian, Izabella Perkins, Herman Friedman, Thomas W Klei. The THC-induced suppression of Th1 polarization in response to Legionella pneumophila infection is not mediated by increases in corticosterone and PGE2. Journal of leukocyte biology. vol 76. issue 4. 2004-11-09. PMID:15258190. |
t helper cell type 1 (th1)-polarizing cytokines are induced by legionella pneumophila infection and are suppressed by pretreatment with marijuana cannabinoids (cb). |
2004-11-09 |
2023-08-12 |
mouse |
| Dorothea Gadzicki, Kirsten R Müller-Vahl, Daniela Heller, Sebastian Ossege, Markus M Nöthen, Johannes Hebebrand, Manfred Stuhrman. Tourette syndrome is not caused by mutations in the central cannabinoid receptor (CNR1) gene. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. vol 127B. issue 1. 2004-11-02. PMID:15108190. |
involvement of the central cannabinoid (cb1) system is suggested because of therapeutic effects of marijuana (cannabis sativa l.) consumption and delta(9)-tetrahydrocannabinol (-thc) treatment in ts patients. |
2004-11-02 |
2023-08-12 |
Not clear |
| Albert D Fraser, David Wort. Urinary excretion profiles of 11-nor-9-carboxy-delta9-tetrahydrocannabinol and 11-hydroxy-delta9-THC: cannabinoid metabolites to creatinine ratio study IV. Forensic science international. vol 143. issue 2-3. 2004-11-01. PMID:15240035. |
further urinary cannabinoid excretion studies are needed to assess whether 11-oh-delta9-thc analyses have a role when assessing previous marijuana or hashish use in chronic users whose urine specimens remain positive for delta9-thc-cooh for an extended period of time after last drug use. |
2004-11-01 |
2023-08-12 |
human |
| Paul F Smit. Medicinal cannabis extracts for the treatment of multiple sclerosis. Current opinion in investigational drugs (London, England : 2000). vol 5. issue 7. 2004-10-18. PMID:15298068. |
however, in the last two years, results of several placebo-controlled clinical trials of orally administered compounds have been published, and these cast doubt on the efficacy of delta9-tetrahydrocannabinol (delta9-thc) in objectively reducing spasticity in ms. by contrast, it has been claimed that sublingually administered cannabis extracts that contain approximately equal concentrations of delta9-thc and cannabidiol, a natural cannabinoid that does not act on the cb1 receptor, can produce a statistically and clinically significant reduction in spasticity, although this claim has yet to be thoroughly validated. |
2004-10-18 |
2023-08-12 |
Not clear |
| Luciano De Petrocellis, Maria Grazia Cascio, Vincenzo Di Marz. The endocannabinoid system: a general view and latest additions. British journal of pharmacology. vol 141. issue 5. 2004-10-14. PMID:14744801. |
after the discovery, in the early 1990s, of specific g-protein-coupled receptors for marijuana's psychoactive principle delta(9)-tetrahydrocannabinol, the cannabinoid receptors, and of their endogenous agonists, the endocannabinoids, a decade of investigations has greatly enlarged our understanding of this altogether new signalling system. |
2004-10-14 |
2023-08-12 |
Not clear |
| P Derkinderen, E Valjent, F Darcel, P Damier, J-A Giraul. [Cannabis and cannabinoid receptors: from pathophysiology to therapeutic options]. Revue neurologique. vol 160. issue 6-7. 2004-10-12. PMID:15247852. |
[cannabis and cannabinoid receptors: from pathophysiology to therapeutic options]. |
2004-10-12 |
2023-08-12 |
Not clear |